Purchase this article with an account.
Manar Addou Regnard, Agnes Glacet-Bernard, Remi Mascali, Eric H Souied; Anti-VEGF treatment of macular edema using a treat-and-extend regimen in retinal vein occlusion in clinical practice. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4158.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate visual and anatomical outcomes of a treat-and-extend regimen in the treatment of macular edema (ME) in retinal vein occlusion (RVO) in clinical practice.
Single-center prospective study of patients with ME secondary to central RVO or its branches treated with intravitreal injections of ranibizumab or aflibercept according to a protocol T & E between 2014 and 2015 and followed for at least 12 months. The data collected were demographic and ophthalmic data before and after treatment (best corrected visual acuity (BCVA), biomicroscopic examination, optical coherence tomography, angiography). The primary end point was mean change in BCVA and central macular thickness (CMT) at the end of follow-up. Secondary out comes were the number of injections and the interval between injections.
Eighteen eyes of 18 patients were included. The mean follow-up was 18 months. The initial average BCVA and CMT were respectively 52.1 ± 18.4 ETDRS letters [15-75], and 517.1 ± 217 microns [257-809]. The mean gain in visual acuity was + 5.42 ± 12.8 letters [-5, +25 ETDRS letters] at the end of follow-up. The mean change in CMT was -172.2 ± 152.2 μm, p = 0.019 [-389, +8 μm]. The average number of intravitreal injections was 8.08 ± 2.99 (median = 8) during the follow-up. The average interval between injections was 4.51 ± 7.68 weeks [from 4 to 20 weeks]. During the first year, the interval between injections increased by 2.16 weeks between M0 and M12 (p = 0.46).
Our study shows the functionnal and anatomical efficacy of anti-VEGF in the treatment of macular edema secondary to RVO using a treat-and-extend regimen in clinical practice. This protocol seems particularly suited to monitoring OVR. It helps prevent recurrence of ME and determine the recurrence interval that is specific to each patient. A larger number of patients is needed to verify these results.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only